Sucampo Pharmaceuticals (SCMP) PT Raised to $19 at Maxim Group

November 15, 2016 7:33 AM EST
Get Alerts SCMP Hot Sheet
Price: $15.20 +1.81%

Rating Summary:
    7 Buy, 4 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade SCMP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Maxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $19.00 (from $17.00).

Kolbert highlighted:

  • Sucampo reported 3Q16 results with total revenues of $57.9M, up 11% sequentially, which we consider to be good sequential growth. Total revenues included product sales of $31.6M ($29.1M from AMITIZA) and royalty revenue of $20.8M from Takeda. The quarterly revenues include an additional $13.3M from the R-Tech Ueno acquisition. While AMITIZA total prescriptions were down slightly in the quarter to 374,194 (-1.4% YoY), revenues were up as Sucampo continues to integrate R-Tech Ueno. A great acquisition for the company, in our opinion.
  • Net income was $8.1M or $0.19 per share on a GAAP basis. Adjusted net income, excluding restructuring impairment, amortization and other expenses, was $12.4M or $0.28 per share. EBITDA for the quarter was $35.6M vs. $11.9M in the same period last year. Adjusted EBITDA was reported at $28.8M vs. $14.6M in 3Q15. The company ended the quarter with $154M in cash and cash equivalents and $209M in notes payable.
  • Full-year 2016 and preliminary 2017 guidance. Sucampo raised guidance for 2016: total revenues of $220M-$225M from $195M-$205M; adjusted net income of $50M-$55M from $45M-$50M; adjusted EPS of $1.20-$1.25 from $0.97-$1.07; and adjusted EBITDA of $110M-$115M from $100M-$105M. The new guidance includes one-time $10M milestone revenue in 4Q16 related to achieving the sales milestone from Mylan for AMITIZA sales in Japan. Sucampo also provided 2017 guidance on total revenue of $220M-$230M; adjusted net income of $75M-$85M; and adjusted EBITDA of $145M-$155M.
  • Model revisions, raising price target. Our model has been revised for certain non-GAAP adjustments. As such, our adjusted 4Q16 and full-year non-GAAP EPS estimates are $0.48 and $1.21, respectively, and inline with company guidance. In addition, we have rolled our valuation metrics forward to 2017. As a result, our price target increases to $19, from $17.

For an analyst ratings summary and ratings history on Sucampo Pharmaceuticals click here. For more ratings news on Sucampo Pharmaceuticals click here.

Shares of Sucampo Pharmaceuticals closed at $15.95 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Maxim Group, Definitive Agreement

Add Your Comment